THE USE OF A TRANSCATHETER AORTIC VALVE TO REPLACE A DEFECTIVE AORTIC VALVE WITHOUT OPEN-HEART SURGERY Natalie Garda and Adam Cotter Heart disease is the.

Slides:



Advertisements
Similar presentations
Pinhas (Peter) Dartal 01 June QA role in development of Percutaneous Aortic Valve prosthesis.
Advertisements

STS 2015 John V. Conte, MD Professor of Surgery Johns Hopkins University School of Medicine On Behalf of the CoreValve US Investigators Transcatheter Aortic.
ATS 3f® Aortic Bioprosthesis
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
PICO Question In patients over the age of 65 with symptomatic aortic stenosis, will standard aortic valve replacement or transcatheter aortic valve replacement.
Arrhythmia Treatment …which you researched! Coronary Artery Bypass Surgery Angioplasty Valve Replacement Aneurysm Repair Transplant.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Diagnosis and Treatment When a person enters an emergency ward with a heart or cardiovascular problem, there are procedures to be followed.
Lesson 4 What is the treatment for Coronary Artery Disease?
Trans-catheter Aortic Valve Replacement: a UK update. Dr Martyn Thomas Guys and St Thomas’ Hospital.
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
Vanessa Beretta & Dan Fleming. About CHD A congenital heart defect also known as CHD is a defect in the structure of the heart and great vessels. Most.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.
Cardiothoracic Surgery. Topics Valvotomy and valve replacement Open heart surgery and cardiac bypass surgery Correction of congenital heart diseases Heart.
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III.
Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis David H. Adams et al (U.S. CoreValve Clinical Investigators) Journal Club November.
Trancatheter Aortic Valve Implantation (TAVI)
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
VIRTUAL SIMULATION OF TRANSCATHETER AORTIC VALVE IMPLANTATION Jenna Smetana and Jessica Sider, Swanson School of Engineering THE TAVI PROCEDURE IS FEASIBLE.
4.4.1 Unblocking the Vessel.
TREATING CARDIOVASCULAR DISEASES. Target: I will be able to describe treatments cardiovascular diseases Pg. 59 Treatments for Cardiovascular Diseases:
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transcatheter Valve-in-Valve and Valve-in-Ring for.
EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.
| rejuveindiameditour.com.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Aortic Valve Replacement Will Become.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal Implantation Depth and Adherence to Guidelines.
VSD post TAVR: Mechanisms, Presentation and Management
PERCUTANEOUS PULMONARY VALVE REPLACEMENT:
David R. Holmes, MD, FACC, Michael J
A: The Edward SAPIEN balloon expandable valve (Edwards Lifesciences, Irvine, CA) incorporates a stainless steel frame, bovine pericardial leaflets, and.
Use of Postmarket Data to Support Premarket Approvals
Percutaneous valve devices
Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN.
Is Transoesophageal Echocardiography during TAVR Essential?
Design & Product Development Larry L Wood
Are we ready to perform TAVI in Intermediate Risk Patients?
Updates From NOTION: The First All-Comer TAVR Trial
Transcatheter Aortic Valve-in-Valve Implantation for Patients With Degenerative Surgical Bioprosthetic Valves  Danny Dvir, MD, Marco Barbanti, MD, John.
Are we ready for expanding TAVI indications to moderate and low risk
TAVR-Endocarditis Tarek Chami, MD
David R. Holmes, MD, Michael J
Review of the Latest OUS Data from the Self-Expanding Valve Studies
30-Day Safety and Echocardiographic Outcomes Following Transcatheter Aortic Valve Replacement with the Self-Expanding Repositionable Evolut PRO System.
Copyright © 2014 American Medical Association. All rights reserved.
From: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve ReplacementA Systematic Review and Meta-analysis Ann Intern Med. 2016;165(5):
Direct Flow Medical Experience with a Conformable, Repositionable Retrievable Percutaneous Aortic Valve Reginald Low MD University of California, Davis.
Opportunities to Study Valve Iterations and Modifications in the US
Insights from the NCDR® STS/ACC TVT Registry.
CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
Is Open Heart Surgery Too Risky For You? Opt for a Minimally Invasive Procedure.
The Ever-Expanding Patient Pool for TAVR:
Nat. Rev. Cardiol. doi: /nrcardio
Nat. Rev. Cardiol. doi: /nrcardio
Percutaneous aortic valves: Effective in inoperable patients, what price in high-risk patients?  Lars G. Svensson, MD, PhD  The Journal of Thoracic and.
Transcatheter valve insertion in a model of enlarged right ventricular outflow tracts  Adeline Basquin, MD, Emmanuelle Pineau, MD, Louise Galmiche, MD,
David R. Holmes, MD, FACC, Michael J
Nat. Rev. Cardiol. doi: /nrcardio
Transatlantic editorial on transcatheter aortic valve replacement
Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.
Figure 1 Types of surgical and transcatheter aortic valves
A.A. Klein, S.T. Webb, S. Tsui, C. Sudarshan, L. Shapiro, C. Densem 
Cardiac Critical Care After Transcatheter Aortic Valve Replacement
Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients.
David R. Holmes, MD, Michael J
Aortic and innominate routes for transcatheter aortic valve implantation  Jean Porterie, MD, Nicolas Mayeur, MD, PhD, Thibaut Lhermusier, MD, PhD, Nicolas.
Matias B. Yudi et al. JACC 2018;71:
Commentary: When a choice is not an echo
Novel treatment for critical aortic stenosis with severe aortic root calcification and coronary disease: Combined left internal thoracic artery graft.
Presentation transcript:

THE USE OF A TRANSCATHETER AORTIC VALVE TO REPLACE A DEFECTIVE AORTIC VALVE WITHOUT OPEN-HEART SURGERY Natalie Garda and Adam Cotter Heart disease is the leading cause of death in America, killing over 610,000 people a year [1]. Many of these deaths are contributed to a condition called aortic stenosis, which causes narrowing and calcification of the aortic valve as well as obstruction of blood flow [2]. An image of a normal versus a stenotic aortic valve is shown below in figure 1. FIGURE 1 [2] Normal aortic valve (left) and Stenotic aortic valve (right) TRANSCATHETER AORTIC VALVE IMPLANTATIONS (TAVIs) Transcatheter Aortic Valve Implantations (TAVIs) are biomedical- engineered devices that replace the biological function of the aortic heart valve without the need for an open heart surgery [3]. This valve is inserted in a minimally invasive manner through one of four arteries and only requires an incision in the more superficial layers of tissue [4]. The four different access points/arteries are shown in figure 2 and the advantages and disadvantages of each point are outlined in the chart below. FIGURE 2 [2] CHART 1 [5] TAVI Access Points Due to the fact that the transfemoral artery is the easiest to access and requires the least invasive procedure, the transfemoral approach tends to be the optimal choice [4[. THE SAPIEN AND THE COREVALVE Currently, two different types of TAVIs are commercially available for patient use. These two types include a balloon expandable model (Edwards SAPIEN) and a self-expandable model (MedTronic CoreValve) [6]. These two models are displayed in figure 3 FIGURE 3 [7] The Edwards SAPIEN device consists of a balloon inside of a stainless steel stent, all attached to a delivery catheter. The framework of the device is a tube with three attachment posts, all connected by beams arranged in a zigzag pattern for optimal support [14]. In addition, exactly like a human aortic valve, this artificial implant consists of three leaflets composed of bovine pericardium as a replacement for human tissue [7]. The MedTronic CoreValve also consists of three leaflets, however they are made from bovine pericardium. The difference between the SAPIEN and the CoreValve is that the latter is composed of a material called Nitinol which allows for self-expansion within the body. The Nitinol material is much more elastic and flexible than the stainless steel in the SAPIEN, which gives it its self- expanding ability [7]. TRANSAORIC VALVE IMPLANTATION (TAVI) VERSUS SURGICAL AORTIC VALVE REPLACEMENT (SAVR) No matter which device is used, the procedure remains generally the same. The only difference between the two devices is that, once into place in the aortic valve, a balloon has to be removed along with the catheter for the SAPIEN, but not for the CoreValve. In addition, there are no notable statistically differences between the use of one device over the other in patient trials [8]. Compared to open-heart surgery, referred to as surgical aortic valve replacement (SAVR), there are major statistical differences. Overall, there is more than a nineteen percent difference in mortality rate between the two procedures, which favors TAVI. There is also a thirteen percent difference in the need for a blood transfusion, again favoring TAVI. However, with the used of TAVI, the likelihood of having a stroke is two and a half times that for SAVR patients [3]. SUSTAINABILITY Over one third of the cases of aortic stenosis that are seen and reported by doctors are inoperable and require alternative measures. This means that by 2050, over 400,000 people per year will require an alternative method such as TAVI in order to replace a damaged aortic valve [3]. These statistics support the fact that TAVIs are vital and sustainable devices in the medical environment as they would provide an increased quality of life for hundreds of thousands of patients worldwide. The self-expanding Medtronic CoreValve (a) and the balloon- expandable Edwards SAPIEN (b) REFERENCES [ 1] CDC Division for Heart Disease and Stroke Prevention. (2015, February 19). “Heart Disease Fact Sheet.” Centers for Disease Control and Prevention. (Online Article). disease.htm [5] disease.htm [2]Medtronic. (2014, April). “CoreValve Transcatheter Aortic Valve Replacement (TAVR) Platform Patient Brochure.” CoreValve Procedure. (Online slideshow). cardio/documents/documents/corevalve_patient_booklet.pdf cardio/documents/documents/corevalve_patient_booklet.pdf [3] A. Pedersen. (2011, November 2). "FDA Approves First Catheter-Based Artificial Heart Valve in the U.S." U.S. Food and Drug Administration. (Online article). ents/ucm htm ents/ucm htm [4] S. Stortecky, C. J. O’Sullivan, L. Buellesfeld, et al. (2013, September 10). “Transcatheter Aortic Valve Implantation: the Transfemoral Access Route is the Default Access.” EuroIntervention. (Online article). pp. S14–S18 [5] “Sternotomy.” (2015). Cardiothoracic Surgery University of Southern California. (Image). sternotomy.htmlhttp:// sternotomy.html [6] Blue Cross Blue Shield (2015, January). “Transcatheter Aortic Valve Implantation for Aortic Stenosis.” Protocol. (Online article). Provider/Protocols/T/prov_prot_ pdf Provider/Protocols/T/prov_prot_ pdf [7] S. Tzamtzis, J. Viquerat, J. Yap, et al. (2013, January). “Numerical Analysis of the Radial Force Produced by the Medtronic-Corevalve and Edwards-SAPIEN after Transcatheter Aortic Valve Implantation (TAVI).” M edical Engineering & Physics. (Online article) pp pp [8] A. Chieffo, G. L. Buchanan, N. M. Van Mieghem, et al. (2013, February 26). “Transcatheter Aortic Valve Implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving System Devices.” Journal of the American College of Cardiology. (Online article) pp pp

REFERENCES [ 1] CDC Division for Heart Disease and Stroke Prevention. (2015, February 19). “Heart Disease Fact Sheet.” Centers for Disease Control and Prevention. (Online Article). [5] [2]Medtronic. (2014, April). “CoreValve Transcatheter Aortic Valve Replacement (TAVR) Platform Patient Brochure.” CoreValve Procedure. (Online slideshow). [3] A. Pedersen. (2011, November 2). "FDA Approves First Catheter-Based Artificial Heart Valve in the U.S." U.S. Food and Drug Administration. (Online article). [4] S. Stortecky, C. J. O’Sullivan, L. Buellesfeld, et al. (2013, September 10). “Transcatheter Aortic Valve Implantation: the Transfemoral Access Route is the Default Access.” EuroIntervention. (Online article). pp. S14–S18 [5] “Sternotomy.” (2015). Cardiothoracic Surgery University of Southern California. (Image). [6] Blue Cross Blue Shield (2015, January). “Transcatheter Aortic Valve Implantation for Aortic Stenosis.” Protocol. (Online article). [7] S. Tzamtzis, J. Viquerat, J. Yap, et al. (2013, January). “Numerical Analysis of the Radial Force Produced by the Medtronic-Corevalve and Edwards-SAPIEN after Transcatheter Aortic Valve Implantation (TAVI).” Medical Engineering & Physics. (Online article). pp pp [8] A. Chieffo, G. L. Buchanan, N. M. Van Mieghem, et al. (2013, February 26). “Transcatheter Aortic Valve Implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving System Devices.” Journal of the American College of Cardiology. (Online article). pp pp

 THE SAPIEN AND THE COREVALVE  Currently, two different types of TAVIs are commercially available for patient use. These two types include a balloon expandable model (Edwards SAPIEN) and a self-expandable model (MedTronic CoreValve) [12]. These two models are displayed in figure 3  The Edwards SAPIEN device consists of a balloon inside of a stainless steel stent, all attached to a delivery catheter. The framework of the device is a tube with three attachment posts, all connected by beams arranged in a zigzag pattern for optimal support [14]. In addition, exactly like a human aortic valve, this artificial implant consists of three leaflets composed of bovine pericardium as a replacement for human tissue [14].  The MedTronic CoreValve also consists of three leaflets, however they are made from bovine pericardium. The difference between the SAPIEN and the CoreValve is that the latter is composed of a material called Nitinol which allows for self-expansion within the body. The Nitinol material is much more elastic and flexible than the stainless steel in the SAPIEN, which gives it its self-expanding ability.